ERBB2 and neoplasm: Pathologically, the predominant subtype was invasive ductal carcinoma (92.2%; <i>n</i> = 83), with hormone-sensitive hormone receptor+/HER2 human epidermal growth factor receptor 2 - tumours being the most frequent among those with available immunohistochemistry (IHC) (58%; n = 18).